Thomas Smith
Stock Analyst at Leerink Partners
(2.25)
# 2,759
Out of 5,241 analysts
59
Total ratings
37.04%
Success rate
10.81%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Thomas Smith
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SYRE Spyre Therapeutics | Maintains: Outperform | $49 → $106 | $66.62 | +59.11% | 1 | Apr 13, 2026 | |
| AGMB AgomAb Therapeutics NV | Initiates: Outperform | $36 | $10.51 | +242.53% | 1 | Mar 3, 2026 | |
| IVA Inventiva | Initiates: Outperform | $12 | $4.91 | +144.40% | 1 | Jan 12, 2026 | |
| ALMS Alumis | Maintains: Outperform | $20 → $32 | $21.53 | +48.66% | 2 | Jan 7, 2026 | |
| EVMN Evommune | Initiates: Outperform | $42 | $21.12 | +98.86% | 1 | Dec 1, 2025 | |
| EQ Equillium | Downgrades: Market Perform | $3 → $1 | $1.77 | -43.34% | 4 | Mar 28, 2025 | |
| QTTB Q32 Bio | Downgrades: Market Perform | $68 → $9 | $6.07 | +48.27% | 2 | Dec 11, 2024 | |
| ACRS Aclaris Therapeutics | Upgrades: Outperform | $2 → $7 | $4.45 | +57.30% | 7 | Nov 19, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Outperform | $39 | $6.09 | +540.39% | 1 | Apr 23, 2024 | |
| SGMT Sagimet Biosciences | Initiates: Outperform | $26 | $6.54 | +297.55% | 1 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $20 | $113.73 | -82.41% | 1 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $430 → $435 | $797.77 | -45.47% | 3 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $36 | $64.07 | -43.81% | 1 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $7 | $2.19 | +219.63% | 4 | Feb 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $21 | $26.29 | -20.12% | 6 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $45 | $15.97 | +181.78% | 2 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $6 | $13.24 | -54.68% | 1 | Nov 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $6 | $2.96 | +102.70% | 2 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $90 → $50 | $11.60 | +331.03% | 3 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $16.37 | +3.85% | 1 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $64 | $30.15 | +112.27% | 2 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $66 → $70 | $17.08 | +309.84% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $26 | $3.58 | +626.26% | 3 | Jun 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $12 | $28.40 | -57.75% | 2 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $80 | $9.91 | +707.27% | 2 | Dec 8, 2020 |
Spyre Therapeutics
Apr 13, 2026
Maintains: Outperform
Price Target: $49 → $106
Current: $66.62
Upside: +59.11%
AgomAb Therapeutics NV
Mar 3, 2026
Initiates: Outperform
Price Target: $36
Current: $10.51
Upside: +242.53%
Inventiva
Jan 12, 2026
Initiates: Outperform
Price Target: $12
Current: $4.91
Upside: +144.40%
Alumis
Jan 7, 2026
Maintains: Outperform
Price Target: $20 → $32
Current: $21.53
Upside: +48.66%
Evommune
Dec 1, 2025
Initiates: Outperform
Price Target: $42
Current: $21.12
Upside: +98.86%
Equillium
Mar 28, 2025
Downgrades: Market Perform
Price Target: $3 → $1
Current: $1.77
Upside: -43.34%
Q32 Bio
Dec 11, 2024
Downgrades: Market Perform
Price Target: $68 → $9
Current: $6.07
Upside: +48.27%
Aclaris Therapeutics
Nov 19, 2024
Upgrades: Outperform
Price Target: $2 → $7
Current: $4.45
Upside: +57.30%
Cartesian Therapeutics
Apr 23, 2024
Initiates: Outperform
Price Target: $39
Current: $6.09
Upside: +540.39%
Sagimet Biosciences
Mar 25, 2024
Initiates: Outperform
Price Target: $26
Current: $6.54
Upside: +297.55%
Nov 14, 2023
Initiates: Outperform
Price Target: $20
Current: $113.73
Upside: -82.41%
Mar 3, 2023
Maintains: Outperform
Price Target: $430 → $435
Current: $797.77
Upside: -45.47%
Feb 28, 2023
Initiates: Outperform
Price Target: $36
Current: $64.07
Upside: -43.81%
Feb 8, 2023
Maintains: Outperform
Price Target: $9 → $7
Current: $2.19
Upside: +219.63%
Feb 6, 2023
Maintains: Outperform
Price Target: $14 → $21
Current: $26.29
Upside: -20.12%
Jan 9, 2023
Maintains: Outperform
Price Target: $40 → $45
Current: $15.97
Upside: +181.78%
Nov 22, 2022
Initiates: Outperform
Price Target: $6
Current: $13.24
Upside: -54.68%
Nov 9, 2022
Maintains: Outperform
Price Target: $5 → $6
Current: $2.96
Upside: +102.70%
Oct 21, 2022
Downgrades: Market Perform
Price Target: $90 → $50
Current: $11.60
Upside: +331.03%
Aug 25, 2022
Initiates: Outperform
Price Target: $17
Current: $16.37
Upside: +3.85%
Aug 9, 2022
Maintains: Outperform
Price Target: $68 → $64
Current: $30.15
Upside: +112.27%
Aug 9, 2022
Maintains: Outperform
Price Target: $66 → $70
Current: $17.08
Upside: +309.84%
Jun 1, 2022
Maintains: Outperform
Price Target: $33 → $26
Current: $3.58
Upside: +626.26%
Apr 28, 2022
Maintains: Outperform
Price Target: $18 → $12
Current: $28.40
Upside: -57.75%
Dec 8, 2020
Maintains: Outperform
Price Target: $42 → $80
Current: $9.91
Upside: +707.27%